ES2132170T3 - Composicion de esteres de l-dopa. - Google Patents

Composicion de esteres de l-dopa.

Info

Publication number
ES2132170T3
ES2132170T3 ES93120894T ES93120894T ES2132170T3 ES 2132170 T3 ES2132170 T3 ES 2132170T3 ES 93120894 T ES93120894 T ES 93120894T ES 93120894 T ES93120894 T ES 93120894T ES 2132170 T3 ES2132170 T3 ES 2132170T3
Authority
ES
Spain
Prior art keywords
composition
active ingredient
dopa
amount
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93120894T
Other languages
English (en)
Inventor
Isaac Milman
Alexander Veinberg
Daphne Atlas
Eldad Melamed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Teva Pharmaceutical Industries Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Teva Pharmaceutical Industries Ltd
Application granted granted Critical
Publication of ES2132170T3 publication Critical patent/ES2132170T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE PRESENTA UNA COMPOSICION QUE COMPRENDE UN PORTADOR FARMACEUTICAMENTE ACEPTABLE Y UN INGREDIENTE ACTIVO, EL INGREDIENTE ACTIVO COMPRENDE UN ESTER DE ETIL DE L-DOPA EN UNA CANTIDAD QUE ES AL MENOS EL 97% DEL PESO DEL INGREDIENTE ACTIVO Y L-DOPA EN UNA CANTIDAD QUE ES MENOR DEL 1% DEL PESO DE DICHO INGREDIENTE ACTIVO. LA INVENCION SUMINISTRA ADEMAS UN PROCESO PARA PREPARAR DICHA COMPOSICION. ADEMAS, ESTA INVENCION SUMINISTRA UN METODO PARA TRATAR A UN PACIENTE QUE SUFRA DE LA ENFERMEDAD DE PARKINSON QUE COMPRENDE LA ADMINISTRACION AL PACIENTE DE UNA COMPOSICION FARMACEUTICA QUE COMPRENDA UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE ESTER DE ETIL DE L-DOPA Y UN PORTADOR FARMACOLOGICAMENTE ACEPTABLE.
ES93120894T 1992-12-24 1993-12-24 Composicion de esteres de l-dopa. Expired - Lifetime ES2132170T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/995,847 US5354885A (en) 1992-12-24 1992-12-24 Process for preparing ethyl ester of L-DOPA

Publications (1)

Publication Number Publication Date
ES2132170T3 true ES2132170T3 (es) 1999-08-16

Family

ID=25542272

Family Applications (2)

Application Number Title Priority Date Filing Date
ES98101741T Expired - Lifetime ES2150294T3 (es) 1992-12-24 1993-12-24 Composicion de esteres de l-dopa.
ES93120894T Expired - Lifetime ES2132170T3 (es) 1992-12-24 1993-12-24 Composicion de esteres de l-dopa.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES98101741T Expired - Lifetime ES2150294T3 (es) 1992-12-24 1993-12-24 Composicion de esteres de l-dopa.

Country Status (21)

Country Link
US (2) US5354885A (es)
EP (2) EP0867179B1 (es)
JP (1) JPH07285860A (es)
CN (1) CN1083262C (es)
AT (2) ATE178793T1 (es)
AU (1) AU684053B2 (es)
CA (1) CA2112160A1 (es)
CY (1) CY2214B1 (es)
DE (2) DE69324466T2 (es)
DK (2) DK0610595T3 (es)
ES (2) ES2150294T3 (es)
FI (1) FI107994B (es)
GR (2) GR3030073T3 (es)
HK (1) HK1012577A1 (es)
HU (1) HU218906B (es)
IL (1) IL108147A (es)
LV (1) LV12766B (es)
NO (1) NO305932B1 (es)
NZ (1) NZ250541A (es)
PT (1) PT867179E (es)
ZA (1) ZA939573B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
WO1997016181A1 (en) * 1995-11-03 1997-05-09 University Of Kentucky Method for the intranasal administration of l-dopa prodrugs
EP0866691B2 (en) * 1995-11-06 2005-01-26 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
AU768154B2 (en) * 1996-10-13 2003-12-04 Neuroderm Ltd Treatment of Parkinson's disease
US6166081A (en) * 1997-10-09 2000-12-26 Kushnir; Moshe Methods and apparatus for treatment of Parkinson's disease
DE69902520T2 (de) * 1998-03-16 2003-04-10 Somerset Pharmaceuticals, Inc. Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
CA2350303A1 (en) 1998-11-10 2000-05-18 Teva Pharmaceutical Industries, Ltd. Process for manufacture of l-dopa ethyl ester
EP1135118A1 (en) * 1998-11-10 2001-09-26 Teva Pharmaceutical Industries Ltd. Dispersible compositions containing l-dopa ethyl ester
RU2157196C1 (ru) * 1999-06-17 2000-10-10 Васильев Виталий Николаевич Фармацевтическая композиция в.н. васильева для восстановления функции симпатико-адреналовой системы, способ оценки индивидуальной эффективности этой композиции для терапии пациентов
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
AU2002346372A1 (en) * 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. Process for the production of l-dopa ethyl ester
US6696600B2 (en) * 2001-11-13 2004-02-24 Teva Pharmaceutical Industries, Ltd. L-DOPA ethyl ester salts and uses thereof
EP2494962B1 (en) 2002-03-20 2014-05-14 Civitas Therapeutics, Inc. Pulmonary delivery for levodopa
US6930137B2 (en) * 2002-05-31 2005-08-16 Fina Technology, Inc. Method of improving blown film processing performance and physical properties
DE10261807A1 (de) 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
WO2004069146A2 (en) * 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
JP2006524708A (ja) * 2003-04-25 2006-11-02 インディヴァス ファーマシューティカルズ，インコーポレーテッド 塩化トロスピウムの投与により連続睡眠を促進するための方法
KR100525358B1 (ko) * 2003-08-21 2005-11-04 주식회사 이엔에프테크놀로지 카르복실 벤조트리아졸 알킬에스테르의 제조방법
DE602004031134D1 (de) * 2003-08-29 2011-03-03 Transform Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
EP1680144B1 (en) * 2003-10-08 2011-10-05 Mallinckrodt LLC Methylphenidate solution and associated methods of administration and production
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
EP3101001B1 (en) * 2006-02-17 2020-04-01 Teva Pharmaceuticals International GmbH Deuterated catecholamine derivatives and medicaments comprising said compounds
CN101623278B (zh) * 2008-07-09 2013-02-27 北京德众万全药物技术开发有限公司 一种含有左旋多巴和盐酸苄丝肼的药物组合物
WO2016179540A1 (en) 2015-05-06 2016-11-10 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
MA42700B1 (fr) * 2015-08-27 2019-12-31 Prexton Therapeutics Sa Dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate
WO2018059739A1 (en) 2016-09-29 2018-04-05 Berlirem Gmbh L-dopa derivatives for the treatment of neurological diseases
PT4039093T (pt) 2021-02-09 2023-10-20 Biobab R&D S L Star Método e utilização de enantiómeros de 3,4-dihidroxifenilalanina (dopa) para aumentar a atratividade das plantas para insetos benéficos

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA716958B (en) * 1970-10-30 1973-01-31 Hoffmann La Roche Phenylalanine amides
US3803120A (en) * 1971-09-28 1974-04-09 Hoffmann La Roche Di-and tripeptides of 3-(3,4-dihydroxyphenyl)-alanine
US3939253A (en) * 1973-11-02 1976-02-17 Interx Research Corporation Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
US4035507A (en) * 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4771073A (en) * 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
EP0252290B1 (en) * 1986-06-10 1992-06-03 CHIESI FARMACEUTICI S.p.A. Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof

Also Published As

Publication number Publication date
LV12766B (en) 2002-03-20
ATE178793T1 (de) 1999-04-15
HUT68498A (en) 1995-06-28
GR3030073T3 (en) 1999-07-30
PT867179E (pt) 2000-12-29
CA2112160A1 (en) 1994-06-25
EP0610595A3 (en) 1994-09-21
AU684053B2 (en) 1997-12-04
HU9303748D0 (en) 1994-04-28
CN1094950A (zh) 1994-11-16
HU218906B (hu) 2000-12-28
FI107994B (fi) 2001-11-15
ATE196081T1 (de) 2000-09-15
JPH07285860A (ja) 1995-10-31
DE69324466D1 (de) 1999-05-20
NO305932B1 (no) 1999-08-23
CN1083262C (zh) 2002-04-24
FI935847A0 (fi) 1993-12-23
IL108147A (en) 1998-09-24
EP0610595A2 (en) 1994-08-17
EP0867179A1 (en) 1998-09-30
HK1012577A1 (en) 1999-08-06
AU5257793A (en) 1994-07-07
CY2214B1 (en) 2002-11-08
GR3034867T3 (en) 2001-02-28
ZA939573B (en) 1994-08-11
ES2150294T3 (es) 2000-11-16
DK0610595T3 (da) 1999-10-25
LV12766A (lv) 2001-12-20
NZ250541A (en) 1995-12-21
US5525631A (en) 1996-06-11
DE69329400D1 (de) 2000-10-12
DE69329400T2 (de) 2001-01-18
FI935847A (fi) 1994-06-25
DE69324466T2 (de) 1999-11-25
IL108147A0 (en) 1994-04-12
EP0867179B1 (en) 2000-09-06
NO934768L (no) 1994-06-27
US5354885A (en) 1994-10-11
EP0610595B1 (en) 1999-04-14
NO934768D0 (no) 1993-12-22
DK0867179T3 (da) 2000-11-06

Similar Documents

Publication Publication Date Title
ES2150294T3 (es) Composicion de esteres de l-dopa.
HUT59313A (en) Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions
IL99699A0 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
IL133585A0 (en) Soluble prodrugs of paclitaxel
HUT47217A (en) Process for producing pharmaceutical compositions containing indol derivatives as active components
CA2114014A1 (en) Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine
UA41906C2 (uk) Спосіб лікування неврологічних порушень, викликаних травмами
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
BG104560A (en) Long active injectable formulations containing hydrogenated castor oil
SG42446A1 (en) Pharmaceutical composition method and device for preventing or treating dry eye or disease caused therefrom
HU9303000D0 (en) Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof
JPS6468320A (en) Remedy for psychotic disease or like and therapeutical solution
WO1993017691A3 (en) Pharmaceutical compositions containing monosialoganglioside gm1 or a derivative thereof suitable for the treatment of parkinson's disease
MY104521A (en) Treatment of depression.
BG100246A (en) N-substituted azaheterocylic carboxylic acids and their esters
CA2135752A1 (en) Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease
CA2237643A1 (en) Therapeutic agent for acute hepatic failure
JPS57167922A (en) Psychotropic drug
MX9801192A (es) Nuevos peptidos opioides.
RU97105771A (ru) Способ лечения сахарного диабета
MY110416A (en) Composition for the treatment of schizophrenia.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 610595

Country of ref document: ES